GSK3B and osteosarcoma: There are currently no WNT modulators in specifically osteosarcoma trials, but there are a few trials targeting WNT in solid tumors (FOG-001, E7386, SM08502, and ST316 (β-catenin inhibitors), CGX1321, RXC004 and ETC-1922159 (porcupine inhibitors), and 9-ING-41 (a GSK-3β inhibitor)) [31].